In 2013, the FDA approved Second Sight Medical’s Argus II, a retinal prosthesis that provides artificial vision by converting images into electrical pulses that can be read by the brain. More than 350 people worldwide received the implant over the last decade, but according to a recent FierceBiotech article, the company has left the users high and dry. Due to financial issues, Second Sight began phasing the Argus II out in 2019. This month, the process was expedited amid the company’s plan to pivot and merge with Nano Precision Medical, a drug delivery implant maker.
Second Sight Leaves Patients with Obsolete Implants
As the company prepares to merge and pivot, 350+ people with Argus II implants will soon be left in the dark.
Feb 21, 2022
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
